XTLB (XTL Biopharmaceuticals) 6-Month Price Index: 1.01 (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTLB XTL Biopharmaceuticals Ltd XTLB
30 GF Score
Price $2.40
! 4 Warning Signs
View Full Analysis

What is XTL Biopharmaceuticals 6-Month Price Index?

XTL Biopharmaceuticals XTLB 30 6-Month Price Index is 1.01 as of Sep. 21, 2026. GuruFocus rates XTLB with a GF Score™ of 30/100. The stock has 4 warning signs investors should review.

6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. It’s calculated by current share price divided by share price 6-months ago. As of today (2026-09-21), XTL Biopharmaceuticals's 6-Month Price Index is 1.01.

XTL Biopharmaceuticals  (NAS:XTLB) 6-Month Price Index Explanation

Price Index (PI) also called momentum. Strategies involving Price Index are also known as momentum strategies as they allow investors to profit from a company’s stock price. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago.

The investment strategy for momentum investors is to buy winners and sell losers. That is, buy stocks that performed well and sell stocks that performed poorly in the past.

XTL Biopharmaceuticals 6-Month Price Index Related Terms

XTLB vs VRTX, REGN, MRNA: 6-Month Price Index Comparison

For the Biotechnology subindustry, XTL Biopharmaceuticals's 6-Month Price Index, along with its competitors' market caps and 6-Month Price Index data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

XTLB
30GF Score
XTL Biopharmaceuticals Ltd XTLB
6-Month Price Index is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

XTL Biopharmaceuticals  (NAS:XTLB) 6-Month Price Index Calculation

6-Month Price Index is calculated as following:

6-Month Price Index=Current Share Price / Share Price 6-Months Ago

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 6-Month Price Index →
What does a 6-Month Price Index of 1.01 mean?
XTL Biopharmaceuticals (XTLB) has a 6-Month Price Index of 1.01 as of Sep. 21, 2026. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on XTL Biopharmaceuticals and its competitors.
Is XTL Biopharmaceuticals' 6-Month Price Index too high?
XTL Biopharmaceuticals' current 6-Month Price Index is 1.01. Overall, XTL Biopharmaceuticals has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does XTL Biopharmaceuticals' 6-Month Price Index compare to VRTX and REGN?
XTL Biopharmaceuticals' 6-Month Price Index of 1.01 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-Month Price Index for a Biotechnology company?
A good 6-Month Price Index depends on the Biotechnology industry context. However, 6-Month Price Index should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-Month Price Index mean?
A high 6-Month Price Index can signal that a stock is expensive relative to its fundamentals. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on XTL Biopharmaceuticals and its competitors. XTL Biopharmaceuticals's current 6-Month Price Index is 1.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XTL Biopharmaceuticals stock overvalued right now?
XTL Biopharmaceuticals (XTLB) has a current 6-Month Price Index of 1.01. The current 6-Month Price Index is 1.01. XTL Biopharmaceuticals' overall GF Score™ is 30/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-Month Price Index calculated?
6-Month Price Index is calculated from a company's financial statements. For XTL Biopharmaceuticals (XTLB), the current 6-Month Price Index is 1.01 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

XTL Biopharmaceuticals Business Description

Other Exchanges XTLB:IsraelHHB0:Germany
Address 26 Ben-Gurion Street, Ramat Gan, ISR, 5112001
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.
30GF Score

Get the complete analysis for XTLB

6-Month Price Index is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.40
Price